Coronary artery disease (CAD) assessment is a vital part of liver transplantation (LT) evaluation, as it allows for identification and medical optimization prior to transplantation. Although aspirin and statins are standard of care for CAD, they are not universally used in cirrhosis due to concerns about adverse events. Per protocol, coronary angiography was performed as part of the LT evaluation in all patients over the age of 50 years or with CAD risk factors, even if they were younger than 50. Optimal CAD medical management was defined as the use of both statin and aspirin, unless a contraindication was documented. Impact of these medications on hepatic decompensation, renal function, gastrointestinal bleeding, and need for transfusion was evaluated. CAD was detected in 84/228 (36.8%) patients. Lipid profile was similar in patients with and without CAD. In patients with CAD, statins were started in 19 (23%), while aspirin was used in 30 (36%) patients. In patients with obstructive or multivessel CAD, statin therapy was used only in 41% and 65%, respectively. Statins were more likely to be prescribed in patients with diabetes (32% versus 15%, P 5 0.05) and history of dyslipidemia (38% versus 15%, P 5 0.02). Use of statin therapy was not linked to hepatic decompensation, hospitalization, or rise in Model for End-Stage Liver Disease (MELD). Similarly, use of aspirin therapy was not associated with increased risk acute variceal hemorrhage, gastrointestinal bleeding, or worsening anemia. In conclusion, in decompensated cirrhosis, lipid profile alone is unable to risk stratify patients with CAD. Statin and aspirin appear to be safe. However, they are significantly underutilized for the management of CAD in this patient population.
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Cardiovascular disease (CVD) is the leading cause of mortality in the United States.
(1) CVD is asymptomatic until the onset of symptoms associated with angina, myocardial infarction, heart failure, and even death. (2) Nearly 1 in 5 patients with no known history of coronary artery disease (CAD) will die when presenting with their first myocardial infarction. (3) Thus, to improve morbidity and mortality associated with CAD, it is important to optimize medical management in patients at risk for having a cardiovascular event. (4) Medical optimization revolves around controlling medical comorbidities (hypertension, diabetes, obesity, and dyslipidemia) and low-dose aspirin therapy. (5, 6) In patients with dyslipidemia, use of 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, is associated with improvement in lipid profile along with a reduction in CVD-related mortality. (7, 8) The benefit in reduction in CVD mortality is beyond the attributed benefit resulting solely from improvement in lipid profile. The pleiotropic effect of statin on CAD-associated mortality is due to its antioxidant, antiinflammatory, and antithrombotic properties. (9, 10) An intimate relationship between CAD and chronic liver disease has been reported. (11, 12) This relationship is best exemplified in nonalcoholic fatty liver disease (NAFLD), which represents the hepatic manifestation of metabolic syndrome. (13, 14) An independent association between CVD-related mortality and NAFLD is linked to severity of liver disease. (11) The exact nexus between CAD and chronic liver disease is not entirely clear but likely results from chronic inflammation, insulin resistance, atherogenic dyslipidemia, impaired vasodilatation at the level of coronary arteries, and coagulation abnormalities. (15) (16) (17) (18) Although CVD is an important cause of morbidity and mortality in patients with chronic liver disease, its medical management in this patient population remains challenging. Use of statins can lead to a mild increase in liver enzymes (19) and rare cases of acute liver failure. (20) Despite an exceedingly low incidence of acute liver failure with statins and a clear cardiovascular mortality benefit, statins are often avoided in patients with chronic liver disease. (21, 22) Furthermore, as patients with chronic liver disease progress to cirrhosis, dyslipidemia improves due to hepatic synthetic failure leading to a falsely normal-appearing serum lipid profile. (16) Aspirin therapy has been associated with risk of renal injury, gastrointestinal bleeding, and worsening anemia. (23, 24) These concerns are heightened in patients with cirrhosis who commonly have thrombocytopenia and coagulation disturbances. (25) Due to thrombocytopenia and hemostatic disturbances, patients with cirrhosis are at risk for bleeding complications, which may potentially be worsened by use of aspirin therapy. Our group recently showed that nearly 1 in 3 patients with decompensated cirrhosis undergoing liver transplant evaluation (LTE) had CAD. (26) However, currently there are limited data regarding the medical management of CAD in patients with cirrhosis and the safety of statin and aspirin therapy in this high-risk patient population. To address these significant gaps in knowledge, the current study was conducted in patients with decompensated cirrhosis to evaluate: (1) the link between dyslipidemia and CAD, (2) the prevalence of use of statins and aspirin as part of the medical management of CAD, and (3) the safety of statin and aspirin therapy.
Patients and Methods
The current study is a retrospective analysis of patients who were prospectively included in the Virginia Commonwealth University (VCU) natural history study of patients undergoing LTE. The study was approved by the institutional review board at VCU. All authors reviewed and approved the manuscript prior to submission.
PATIENT POPULATION
The current analysis was restricted to all patients with cirrhosis who were evaluated for liver transplantation (LT) at VCU between January 1, 2011 and December 31, 2014. Per institutional protocol, all patients over the age of 50, prior history of CAD, or risk factors for CAD underwent elective, protocolled coronary angiography for CVD risk assessment as part of LTE. Risk factors for CAD included family history, high-risk metabolic comorbid conditions (hypertension, diabetes mellitus, obesity, metabolic syndrome, dyslipidemia), and smoking history. Additionally, in patients age <50 without coronary risk factors, coronary angiography was also indicated for those who have an abnormal or nondiagnostic cardiac stress test. Since CAD can only be assessed with certainty with coronary angiography, only patients with coronary angiography were included in the current analysis. Patients who did not undergo coronary angiography as part of their LTE were excluded.
CORONARY ARTERY DISEASE
The severity and distribution of CAD were defined according to Coronary Artery Surgery Study criteria. (27) Presence of CAD was defined as any degree of stenosis in any of the coronary arteries as determined by visual inspection on coronary angiography. Stenosis 50% was considered obstructive disease, while stenosis <50% was considered nonobstructive. Severe 1-, 2-, or 3-vessel diseases were defined as 70% obstruction in 1, 2, or 3 of the major coronary artery distribution that includes left anterior descending (LAD), circumflex and right coronary artery (RCA) disease and its main branches, respectively. A stenosis 50% in the left main artery distribution was considered significant; these patients were considered to have a 2-or 3-vessel disease based on absence or presence of RCA stenosis.
MEDICAL MANAGEMENT OF CAD
Patients were considered to have known CAD if it was documented in their medical records. In patients with known CAD, optimal medical therapy was considered the use of statin, as well as aspirin therapy. (5, 6) Statin use was determined by reviewing clinical notes (ie, hepatology, primary care, transplant surgery, endocrine, etc.), as well as a review of the prescriptions filled at the pharmacy. Similarly, aspirin use was quantified by patient interview and review of clinical notes. Unless there were clinical documentations of complications associated with either aspirin or statin therapy (for example, intolerance, recurrent GI bleeding), patients with CAD who were not on aspirin or statins were considered suboptimally managed. Similarly, patients who were diagnosed with CAD after coronary angiography as part of LTE were considered suboptimally managed if they were not on a statin or aspirin therapy, unless a contraindication was documented. All patients were followed with scheduled clinical visits at least once every 3 months. The medical records of all patients were reviewed for hospitalizations, procedures (such as endoscopy or paracentesis), or unscheduled clinical visits.
STATISTICAL ANALYSIS
Data are reported as means and standard deviations (SD), numbers and percentages or odds ratios (ORs) with 95% confidence intervals (CIs). Means for nonparametric distribution were compared using either the Mann-Whitney U test or Kruskal-Wallis test as appropriate. The chi-squared test was used to compare proportions between groups. To evaluate the safety of statin therapy in patients with decompensated cirrhosis, patients on either statin or aspirin therapy were compared with those not on therapy. Patients on aspirin therapy for an indication other than CVD prophylaxis (ie, history of hepatic vein thrombosis) were excluded from the analysis. A comparison between the 2 groups was made with regards to the biochemical profile (liver chemistry, bilirubin, creatinine, blood urea nitrogen, hemoglobin, platelets) and clinical outcomes including hospital admissions, gastrointestinal bleeding, hepatic decompensation, or mortality. Since patients with decompensated cirrhosis are at increased risk of short-term mortality in the absence of LT, the follow-up time to determine decompensation was 6 months, LT, or death. Hepatic decompensation was defined as either new or hospital admission for hepatic encephalopathy, ascites, acute variceal hemorrhage, or spontaneous bacterial peritonitis. To evaluate the impact of aspirin therapy on renal function, serum creatinine was compared 6 months after initiation of aspirin therapy. Rates of renal failure requiring dialysis and hospital admission for acute renal failure were also compared up to 6 months after coronary angiography. To assess the impact of aspirin therapy on anemia, serum hemoglobin levels and need for transfusion in the absence of clinically overt bleeding were compared in patients on aspirin therapy with those not on aspirin up to 6 months after coronary angiography. Similarly, rates of gastrointestinal bleeding including acute variceal hemorrhage were compared. Nominal, 2-sided P values were used and considered significant if P < 0.05. Statistical analysis was performed using Statistical Package for the Social Science (SPSS).
Results

PATIENT CHARACTERISTICS
This cohort has been published previously. (26) Briefly, out of a total of 341 patients who were referred for LTE during the study period, 228 patients met the inclusion criteria. Of the 113 patients who did not undergo coronary angiography, the leading causes were LTE suspended due to clinical improvement (n 5 26) and age <50 (n 5 23). The majority of the cohort was comprised of males (64.5%), and the mean age at the time of LTE was 57 6 6 years. Non-Hispanic Caucasians and African Americans comprised 76.8% and 21.9% of the cohort, respectively. The mean Model for End-Stage Liver Disease (MELD) score was 16 6 6. The mean serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides were 39 6 17 mg/dL, 82 6 47 mg/dL, 144 6 72 mg/dL, and 107 6 66 mg/dL, respectively ( 
CORONARY ARTERY DISEASE
Coronary artery disease (CAD) was present by coronary angiography in 84 patients (36.8%), and 44 patients (19.3%) had obstructive CAD (Table 1 ). Only 9 patients (11%) were aware of their diagnosis prior to pretransplant cardiac evaluation. The serum lipid profile (drawn at the time of initial transplant evaluation) in patients with angiographically documented CAD was similar to those without CAD (Fig. 1) . Interestingly, total serum cholesterol was lower in patients with obstructive disease when compared with those with nonobstructive CAD or no CAD (131 6 69 mg/dL versus 178 6 119 mg/dL versus 140 6 51mg/dL; P 5 0.019) (Fig. 1A) . Serum HDL-C levels were significantly lower in patients with obstructive CAD when compared with those with nonobstructive CAD or no CAD (33 6 17 mg/dL versus 40 6 15 mg/dL versus 41 6 16 mg/dL; P 5 0.05). No differences in serum LDL-C and triglycerides were noted with the severity of CAD (Figs. 1C, D) . CAD was more common in patients with NASH cirrhosis compared with other etiologies. Similarly, almost all cases with multivessel CAD had NASH as the underlying etiology of liver disease. The only factors associated with prior knowledge of underlying CAD included the history of prior dyslipidemia (r 5 0.23, P 5 0.03) and hypertension (r 5 0.25, P 5 002). Patients who were aware of their diagnosis were more likely to have obstructive disease (18% versus 3%, P 5 0.03). The diagnosis in a majority (89%) of the patients with CAD was established only after a per protocol coronary angiography.
MEDICAL MANAGEMENT OF CAD
In patients with a known history of CAD (n 5 9), only 2 patients were on statin therapy, while 5 were on aspirin prophylaxis. Of the patients with a known CAD who were not on statins or aspirin, there were no documented contraindications to these therapies. After the diagnosis of CAD in patients undergoing per protocol coronary angiography, 19 patients were placed on statin therapy (23%), while 65 patients were not ( Fig. 2A) . Additionally, among patients with obstructive CAD (n 5 44) or severe multivessel disease (n 5 17), only 18/44 (41%) and 11/17 (65%) were started on statin therapy. Similarly, use of aspirin therapy was documented in 30 (36%), 28 (64%), and 13 (77%) of patients with any CAD, obstructive CAD, and multivessel CAD, respectively (Fig. 2B) . To determine if presence of baseline portal hypertension related parameters or the bleeding profile affected aspirin use, we compared these parameters in the patients started on aspirin therapy versus those who were not started on aspirin therapy. The 2 groups were similar with regards to portal hypertension (presence of varices, history of variceal bleeding, hepatic encephalopathy, ascites, etc.) as well as coagulation and serum platelets (Supporting Table S1 ). There were no documented contraindications for statin therapy use in patients not started on statin therapy. In patients who underwent percutaneous coronary artery intervention (n 5 21), statin therapy was only used in 8 patients (38%) while aspirin therapy was used in all patients. In patients with CAD, use of statin therapy was more common in patients with DM (32% versus 15%; P 5 0.05) and history of dyslipidemia (38% versus 15%, P 5 0.02). Similarly, in patients with CAD, aspirin use was more common in patients with DM (51% versus 23%, P 5 0.01). In patients with CAD, use of statin or aspirin therapy was not associated with family history of CAD, hypertension, obesity, smoking status, education level, or presence of complications of portal hypertension. Finally, only 1 patient had a CVD event in the form of non-ST-segment elevation acute coronary syndrome and was not on statin or aspirin therapy. No CVD events were observed in patients who were on either aspirin, statins, or both. 
BASELINE LABORATORY VALUES VERSUS STATINS AND ASPIRIN USE
Baseline serum lipid profile prior to statin treatment including HDL-C, LDL-C, total cholesterol, and serum triglyceride levels were similar in patients with CAD who were on statin therapy compared with those who were not (Table 2) . Interesting, patients on statin therapy had lower serum aspartate aminotransferase (AST), total bilirubin, and conjugated bilirubin. Similarly, patients on aspirin were likely to have lower serum alanine transaminase (ALT) (46 IU/L versus 61 IU/L; P 5 0.02), AST (70 IU/L versus 93 IU/L; P 5 0.04), total bilirubin (2.2 mg/dL versus 3.6 mg/dL; P 5 0.01), and conjugated bilirubin (1.1 mg/dL versus 1.9 mg/dL; P<0.01). Serum platelets, hemoglobin, and prevalence of varices or history of variceal hemorrhage did not impact the use of aspirin or statin therapy.
SAFETY OF STATINS AND ASPIRIN IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
A total of 19 and 30 patients out of 84 patients with CAD were on statin and aspirin therapy, respectively. Use of statin therapy was not associated with any significant increase in serum AST, ALT, bilirubin, or MELD score up to 6 months after initiation of therapy (Table 3) . Aspirin use was not associated with worsening serum creatinine or acute renal failure requiring hospitalization or dialysis. A significant drop in platelet count was noted 6 months after initiation of aspirin therapy where the mean platelet count dropped from 125 3 10 9 /L to 95 10 9 /L (P 5 0.004), while no changes in platelet counts were noted in patients who were not on aspirin therapy after 6 months of followup (baseline 102 3 10 9 /L versus 6-month follow-up 107 3 10 9 /L; P 5 0.562). Aspirin use was not associated with subclinical bleeding (reduction in serum hemoglobin or need for blood transfusion), overt gastrointestinal bleeding, or acute variceal hemorrhage at follow-up. Statin use was not associated with increased risk of hepatic decompensation characterized by new onset hepatic encephalopathy, acute variceal hemorrhage, ascites, or spontaneous bacterial peritonitis. The risk of hospitalization in the aspirin, statin, and no aspirin/statin groups were similar at follow-up (20% versus 32% versus 25%, P 5 0.26). The proportions of patients who either died or received LT were not affected by the use of aspirin or statin therapy (Table  3) . 
NOTE: Data are given as n (%) or mean 6 SD. Bilirubin, mg/dL 4.0 6 6.3 3.4 6 4.4 3.5 6 5.6 International normalized ratio 1.6 6 0.9 1.7 6 0.7 1.7 6 0.8 Creatinine, mg/dL 1.3 6 1.5 1.6 6 1.4 1.7 6 1.6 Hemoglobin, g/dL 11.0 6 2. 
Discussion
CAD-associated mortality had been steadily increasing until the 1980s when it began to decline for the first time. (1, 28) This stems from the culmination of efforts at improving access to care, development of statins, optimizing medical management, and patient and physician education. (29, 30) The role of optimizing medical management cannot be emphasized enough, as multiple studies have shown that the use of statins and aspirin as both primary and secondary prophylaxis in patients with known CAD and those with risk factors confers a reduction in mortality. (5, 6) Despite an independent relationship between CAD and chronic liver disease, (12, 13) statin therapy is often underutilized in patients with chronic liver disease due to the perceived increased risk of hepatotoxicity. (22) These concerns by clinicians are often heightened in patients with cirrhosis or LT due to their complicated medical history, (31, 32) overshadowing an obvious mortality benefit of statin. (33) In the current study, although CAD was common among patients with decompensated cirrhosis, only a few were aware of their diagnosis. Additionally, in patients with angiographically documented CAD, only a minority of patients was on or was started on optimal medical therapy, which includes both statin and aspirin. Although patients with obstructive CAD and multivessel CAD were more likely to be on optimal therapy, the use of statin and aspirin therapy was not universal even among this high-risk cohort.
Statin therapy is often started in patients with abnormal serum lipid profiles, which allows for additional titration of the statin therapy. (5) Patients with cirrhosis have synthetic hepatic failure resulting in an artificial improvement in the lipid profile. (16) The current study provides further insight into this phenomenon by demonstrating that serum triglycerides, total cholesterol, and LDL-C failed to indicate the presence and severity of CAD. In patients with documented CAD, even in the absence of lipid abnormalities, the use of statin therapy is associated with a significant mortality benefit and is considered standard of care. (5, 7) Medical optimization of any patients, and particularly of decompensated patients with cirrhosis and CAD, is important for several reasons. First, presence and severity of CAD are linked to periopperative and postoperative morbidity and mortality in patients undergoing LT. (34) Second, cardiovascular diseaserelated mortality is an important cause of mortality in patients after transplantation, and use of statin therapy was associated with a reduction in mortality in liver transplant recipients. (33) Several studies support the use of statin therapy due to the impact on CVD events even after relatively small follow-up. (35, 36) The accumulating data from nearly half a century of clinical trials suggest that >90% of CVD events and intervention is due to failure of medical prophylaxis and could have been prevented with appropriate therapy. (37) Although the literature is robust within the field of cardiology, it is less robust in hepatology, and due to small sample size, we are unable to draw any definitive conclusion. Additionally, the impact of statin therapy on plaque stabilization and prevention of CVD events at the time of LT is also unknown, which could potentially be a major added benefit of use of statin therapy in patients with decompensated cirrhosis on the LT waiting list.
A major deterrent against the universal use of statins in patients with chronic liver disease and cirrhosis is fear of liver failure or further hepatic decompensation. There are case reports of statin-induced hepatotoxicity and fulminant hepatic failure; however, these are rare as the number of patients transplanted for statininduced liver failure is exceedingly low. Among 1,198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug-induced liver injury; of them, only 6 were attributed to statins. (20) It is estimated that statin therapy is used in 39.2 million patients in the United States, (38) indicating that statin-induced liver failure is exceedingly uncommon. There are currently no data regarding the safety of statin therapy in patients with decompensated cirrhosis. In a recent meta-analysis of patients with compensated cirrhosis, use of statins was associated with a reduction of portal pressure and no significant increase in hepatic decompensation. (39) In the current cohort study, we build on these data to show that statin therapy does not increase the risk of hepatic decompensation or mortality and is safe to use in patients with decompensated cirrhosis. Similarly, universal use of aspirin therapy in patients with cirrhosis is limited by the potential increased risk of renal failure, gastrointestinal bleeding, and variceal hemorrhage. In the current study, in patients with decompensated cirrhosis and CAD, the use of aspirin therapy was not associated with increased risk of hepatic decompensation, renal failure, and gastrointestinal and variceal bleeding. Aspirin use was associated with a significant reduction in platelet count, likely resulting from consumptive coagulatopathy; however, this was not clinically relevant since serum hemoglobin levels were unaffected and patients on aspirin therapy did not have greater risk of clinically significant bleeding episodes. These findings underscore the safety of lowdose aspirin therapy in patients with decompensated cirrhosis.
Due to the retrospective nature of the study, we are unable to quantify why cirrhotic patients with CAD were not started on statin or aspirin therapy. A better understanding of this is necessary to overcome limitations in improving CAD-related care in patients with cirrhosis. Additionally, we are unable to link the use of statin therapy to perioperative and postoperative outcomes. This limitation results from a relatively low number of patients on statin or aspirin therapy who had LT. Additional studies with larger sample sizes are necessary to explore the impact of statin therapy on major adverse cardiovascular events.
In summary, CAD is common in patients with decompensated cirrhosis and is not captured by the traditional lipid profile. Although statin and aspirin therapy have been shown to improve CAD-related outcomes, they are often underutilized in patients with decompensated cirrhosis with CAD. Finally, statin and aspirin therapy are safe in cirrhosis and do not increase the risk of hepatic decompensation or mortality.
